On October 2, ENDRA Life Sciences (NDRA) filed its S-4. That moves ASP Isotopes’ plan to spin its South African helium and LNG business, Renergen, into a separately listed company called Noble Africa (ticker: NOBA) one step closer to a shareholder vote.
Most coverage stopped at the headline. We didn’t. Over the past week, SEQH Capital Research rebuilt the deal from first principles. We checked every balance-sheet input against ASPI’s Q2 10-Q and built a full project-finance model of the Virginia Gas Project. It runs 78 complete 45-year versions of the project in parallel.
Here’s what we found.
1. The deal values ASPI’s stake at more than ASPI itself
Outside investors are putting about $30M into Noble Africa for roughly 7% of the company. That implies a post-money value of about $429M.
ASPI will own about 89%, which values its stake at ~$381M, or $2.49 per ASPI share.
ASPI’s entire enterprise value today is about $338M. That figure includes ~$79M of third-party QLE convertible notes, which most screens miss. So the deal’s own price for ASPI’s helium stake is 113% of what the market pays for all of ASPI: helium, PET Labs, stable isotopes, Quantum Leap Energy and everything else.
That gap is the starting point of the analysis.
2. The market is pricing Phase 2 at almost exactly breakeven
The real value in Renergen is Phase 2. That’s a ~$1.15B expansion targeting ~900 Mcf/day of liquid helium, roughly 5–7% of global supply according to management.
We modeled it at management’s own helium price assumption of $600/Mcf. The result is a 13.7% return on equity, just below a 16% hurdle for a South African project. Equity breaks even at about $763/Mcf.
Then we ran the model in reverse to ask what helium price the $2.92 share price implies. The answer is $766–768/Mcf.
In other words, the market is valuing Phase 2 at roughly zero above its cost of capital. Any long-term helium contract signed above ~$770/Mcf is value the stock isn’t currently pricing.
For context, the company cites recent spot prints above $2,000/Mcf amid a global supply shock.
3. Every $100 matters
In our model, each $100/Mcf of Phase 2 contract pricing above ~$770 adds $0.15–0.24 per ASPI share.
Valuing Phase 2 the way listed gas assets are usually valued, at 8–10x run-rate earnings rather than a conservative 25-year cash-flow model, gives $3.20–3.71 per share.
Phase 1 also has spot exposure today. About 85% of its helium is uncontracted. Sold at spot, Phase 1 revenue could reach roughly 2x management’s $27M guidance.
4. A few things nobody is talking about
A unit discrepancy. The company’s own footnote describes Phase 1 helium capacity in kilograms. Converted, it comes to about 52 Mcf/day, not the 70 Mcf/day headline.
A debt coverage gap. In Phase 2’s first ramp year, cash flow covers only 0.93x of debt payments under standard amortization. Lenders will want that structured around.
A clear statistical pattern. Across 12 corporate events in 2026, deal and structure news averaged −8.1%. Operational news averaged +7.6%. The difference is statistically significant (p ≈ 0.004).
Insider buying. A director bought 15,000 shares on September 30 at $2.68.
Positioning. Short interest stands at 19.9% of float, with 6.5 days to cover.
What paid subscribers get
1. The full research report (14 pages). Deal anatomy, the October 1 amendment decoded, Phase 2 economics, a 20,000-path Monte Carlo valuation, upside analytics, catalysts and risks.
2. The SEQH ASPI / NDRA Quantitative Model (Excel). It’s fully live, with about 65,800 formulas and every assumption sourced. You can change any input and watch it flow through everything:
five scenarios, including a shortage-pricing case
seven live breakeven solvers
a helium × capex sensitivity grid and tornado chart
lender metrics: debt coverage by year, loan-life coverage, peak equity funding, payback
a sum-of-the-parts valuation by segment
19 built-in integrity checks
3. The Model Companion (19 pages). A tab-by-tab technical walkthrough with screenshots of every analytical sheet and a full formula reference, so you can audit every number yourself.
Monte Carlo results. At current pricing, our simulation centers at $2.88. Under shortage pricing (helium median $1,000/Mcf), the median moves to $3.15 and the 90th percentile to $4.33. The model shows exactly which assumptions drive the gap.
We don’t issue ratings or price targets. We build the analysis and show our work, so you can make your own call with better data than the headline gives you.
SEQH Capital Research is an independent research firm. This article is for informational purposes only and is not investment advice. Model outputs are analytical sensitivities, not price targets or forecasts. SEQH Capital Research and its principals may hold positions in the securities discussed. Data as of the October 2, 2026 close.
LIVE EXCEL MODEL AND PDF LOCATED BELOW:
